TRRI Stock Overview
Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Alzex Neuropharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.10 |
| 52 Week High | US$0.50 |
| 52 Week Low | US$0.10 |
| Beta | 0 |
| 1 Month Change | -33.33% |
| 3 Month Change | -51.81% |
| 1 Year Change | -33.77% |
| 3 Year Change | 212.50% |
| 5 Year Change | 941.67% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| TRRI | US Metals and Mining | US Market | |
|---|---|---|---|
| 7D | 0% | 3.7% | 2.7% |
| 1Y | -33.8% | 29.1% | 26.0% |
Return vs Industry: TRRI underperformed the US Metals and Mining industry which returned 21.9% over the past year.
Return vs Market: TRRI underperformed the US Market which returned 25% over the past year.
Price Volatility
| TRRI volatility | |
|---|---|
| TRRI Average Weekly Movement | n/a |
| Metals and Mining Industry Average Movement | 8.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRRI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TRRI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | n/a | Robert Rosner | www.trinresinc.com |
Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada.
Alzex Neuropharma Inc. Fundamentals Summary
| TRRI fundamental statistics | |
|---|---|
| Market cap | US$150.53k |
| Earnings (TTM) | US$32.05k |
| Revenue (TTM) | US$4.73m |
0.0x
P/E Ratio0.0x
P/S RatioIs TRRI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRRI income statement (TTM) | |
|---|---|
| Revenue | US$4.73m |
| Cost of Revenue | US$4.30m |
| Gross Profit | US$430.14k |
| Other Expenses | US$398.09k |
| Earnings | US$32.05k |
Last Reported Earnings
Dec 31, 2011
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did TRRI perform over the long term?
See historical performance and comparison